Liver transplantation for hepatitis B virus: Decreasing indication and changing trends

Table 1 Characteristics of the study population, both overall and grouped by recurrence n (%)

Characteristics
Age (yr)	50.6 ± 11.0	44.3 ± 16.2	51.4 ± 9.9	0.022
Gender
Male	106 (80)	14 (13)	92 (87)	0.16
Female	27 (20)	1 (3.7)	26 (96)
Posttransplantation follow-up (mo)	82 (1-274)1	206 (74-274)	53 (1-254)	< 0.0001
Pretransplantation HBsAg
Negative	6 (5)	0	6 (5)	0.37
Positive	126 (95)	15 (100)	111 (95)
Pretransplantation HBeAg
Negative	108 (81)	6 (40)	102 (87)	< 0.00012
Positive	24 (19)	9 (60)	15 (134)
Pretransplant HBV DNA
Negative	86 (73)	4 (60)	82 (73)	0.03
Positive	36 (27)	6 (60)	30 (26)
HBIG duration (mo)1	14 (1-140)	14 (1-140)	14 (1-132)	0.83
MELD score	20.8 ± 7.6	19.2 ± 7.7	21.0 ± 7.6	0.39
Posttransplantation HBsAg
Negative	114 (88)	3 (20)	111 (97)	< 0.00012
Positive	16 (12)	12 (80)	4 (3)
Posttransplant HBeAg
Negative	122 (96)	11 (73)	111 (99)	< 0.00012
Positive	5 (4)	4 (5)	1 (1)
HDV coinfection
Negative	70 (69)	8 (80)	62 (67)	0.41
Positive	32 (31)	2 (20)	30 (33)

¹The results are expressed as the median (range);

²Significant at P < 0.05. HDV: Hepatitis delta virus; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus.

Table 2 Characteristics of the study population grouped by the presence of hepatocellular carcinoma n (%)

Variable	No HCC	HCC	P value
	n = 89 (67)	n = 44 (33)
Age (yr)	48.4 ± 11.3	55.2 ± 8.6	0.00071
Gender
Male	69 (78)	37 (84)	0.38
Female	20 (22)	7 (16)
Pretransplant HBsAg
Negative	4 (5)	2 (5)	1.00
Positive	84 (95)	42 (95)
Pretransplant HBeAg
Negative	69 (82)	33 (79)	0.63
Positive	15 (18)	15 (21)
Pretransplant HBV DNA
Negative	57 (72)	29 (67)	0.59
Positive	22 (28)	14 (33)
MELD score	22.2 ± 6.9	18.0 ± 8.2	0.0021
Posttransplant HBsAg
Negative	75 (86)	39 (91)	0.46
Positive	12 (14)	4 (9)
Posttransplant HBeAg
Negative	81 (95)	41 (98)	0.53
Positive	4 (5)	1 (2)
HDV coinfection
Negative	50 (68)	20 (71)	0.71
Positive	24 (32)	8 (29)

¹Significant at P < 0.05. HDV: Hepatitis delta virus; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus.

Table 3 Comparison of indications for transplantation before and after January 2007

	Before January 2007	After January 2007	P value
	(n = 64)	(n = 69)
Transplantations for well-compensated HCC	6	19	0.007
Transplantations for liver decompensation without HCC	46	43	Not significant

HCC: Hepatocellular carcinoma.